Schanz et al reported a comprehensive scoring system based on cytogenetics for patients with primary myelodysplasia (MDS) or oligoblastic acute myeloid leukemia (AML). This can help to identify a patient who may benefit from more aggressive management. The authors are from multiple institutions from around the world.
Patient selection: primary myelodysplastic syndrome or oligoblastic acute myeloid leukemia
Parameters:
(1) total number of cytogenetic abnormalities
(2) specific cytogenetic abnormalities
Total Number |
Specific Cytogenetic Abnormalities |
Prognosis |
>= 4 |
NA |
very poor |
3 |
NA |
poor |
2 |
del(5q) OR -7 |
poor |
2 |
del(7q) |
good |
2 |
other |
intermediate |
1 |
inv(3) OR t(3q) OR del(3q) OR -7 |
poor |
1 |
del(11q) OR -Y |
very good |
1 |
del(5q) OR del(12p) OR del(20q) |
good |
1 |
del(7q) OR +8 OR i(17q) OR +19 |
intermediate |
1 |
independent clones |
intermediate |
1 |
other |
intermediate |
0 (none) |
NA |
good |
Specialty: Hematology Oncology, Clinical Laboratory
ICD-10: ,